Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Allogeneic Mesenchymal Stromal Cell
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Recipient : Cipla
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Stempeucel® has been developed by Stempeutics and is the first allogeneic cell therapy product to be approved for commercial use in India and the first stem cell product to be approved globally for CLI treatment. Cipla will market and distribute in Stem...
Product Name : Stempeucel
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 20, 2020
Lead Product(s) : Allogeneic Mesenchymal Stromal Cell
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Recipient : Cipla
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Novumcella
Deal Size : Undisclosed
Deal Type : Agreement
Details : As per the agreement, Novumcella will initially provide regulatory support services to Stempeutics for getting approval from PMDA, Japan for conduct of bridge study in Japan for commercializing Stempeucel® product for Buerger’s Disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 28, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Novumcella
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Stempeucel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 17, 2017
Lead Product(s) : Stempeucel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allogeneic Mesenchymal Stem Cell
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver Cirrhosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 03, 2012
Lead Product(s) : Allogeneic Mesenchymal Stem Cell
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allogeneic Mesenchymal Stem Cell
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Stempeucel
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 02, 2011
Lead Product(s) : Allogeneic Mesenchymal Stem Cell
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adult Allogeneic Mesenchymal Stem Cell
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Allogeneic Mesenchymal Stem Cells in Osteoarthritis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 18, 2011
Lead Product(s) : Adult Allogeneic Mesenchymal Stem Cell
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adult Allogeneic Mesenchymal Stem Cell
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Stempeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Allogeneic Mesenchymal Stem Cells for Osteoarthritis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 07, 2011
Lead Product(s) : Adult Allogeneic Mesenchymal Stem Cell
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Stempeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mesenchymal Stem Cell
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Stempeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Ex Vivo Cultured Adult Allogenic MSCs in Ischemic Cerebral Stroke
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 24, 2010
Lead Product(s) : Mesenchymal Stem Cell
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Stempeutics
Deal Size : Inapplicable
Deal Type : Inapplicable